Pazufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pazufloxacin
Accession Number
DB11774
Type
Small Molecule
Groups
Investigational
Description

Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

Structure
Thumb
Synonyms
Not Available
External IDs
T-3761
Product Ingredients
IngredientUNIICASInChI Key
Pazufloxacin Mesilate2XI226J1HS163680-77-1UDHGFPATQWQARM-FJXQXJEOSA-N
Categories
UNII
4CZ1R38NDI
CAS number
127045-41-4
Weight
Average: 318.304
Monoisotopic: 318.101585134
Chemical Formula
C16H15FN2O4
InChI Key
XAGMUUZPGZWTRP-ZETCQYMHSA-N
InChI
InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
IUPAC Name
(2S)-6-(1-aminocyclopropyl)-7-fluoro-2-methyl-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
[H][C@]1(C)COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2C1(N)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Pazufloxacin.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pazufloxacin.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pazufloxacin.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Pazufloxacin.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Pazufloxacin.
AceclofenacAceclofenac may increase the neuroexcitatory activities of Pazufloxacin.
AcemetacinAcemetacin may increase the neuroexcitatory activities of Pazufloxacin.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Pazufloxacin.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Pazufloxacin.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazufloxacin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
65957
PubChem Substance
347828126
ChemSpider
59360
ChEBI
94700
ChEMBL
CHEMBL240163
Wikipedia
Pazufloxacin
ATC Codes
J01MA18 — Pazufloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentOtitis Media (OM)1
2CompletedTreatmentConjunctivitis, Bacterial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.41 mg/mLALOGPS
logP-0.51ALOGPS
logP-1ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)5.59ChemAxon
pKa (Strongest Basic)8.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.86 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity80.03 m3·mol-1ChemAxon
Polarizability30.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0296000000-cc353f5c3e0ddf62f272

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Alkyl aryl ethers / Aralkylamines / Aryl fluorides / Benzenoids
show 12 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid or derivatives / Pyridine carboxylic acid / Aralkylamine / Alkyl aryl ether
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Book section [Link]

Drug created on October 20, 2016 14:47 / Updated on August 18, 2018 15:07